Injective (INJ) is currently priced at $3.25, reflecting a 3.16% increase over the last 24 hours. The daily trading range is narrow, with a high of $3.34 and a low of $3.14, indicating relatively stable price action.

The trading volume of approximately $49.73 million suggests a healthy market interest, with a volume-to-market cap ratio of 15.31%. This level of volume supports the recent price movement and indicates that the market is engaged in trading activity.

Technical indicators show mixed signals, with the 8-hour Simple Moving Average (SMA) at $3.28 reflecting a slight decline of 0.87%. However, longer-term SMAs show a positive trend, with the 55 SMA at $3.12 and the 144 SMA at $3.07 both indicating upward momentum, up 4.03% and 5.99%, respectively.

The 1-hour Relative Strength Index (RSI) sits at 62, suggesting that INJ is approaching overbought territory, while the 7-day RSI at 58 indicates it is still in a neutral range. This divergence suggests that while short-term momentum may be fading, the medium-term trend remains healthy.

Over the past week, INJ has gained over 10%, indicating strong bullish sentiment, despite a minor decline over the last 30 days. The all-time high of $52.62 set in March 2024 highlights significant potential for future growth, although the current price is substantially lower, reflecting market volatility.

In conclusion, the combination of strong short-term gains, healthy trading volume, and supportive long-term moving averages indicates a bullish trend for Injective. Therefore, the rating for INJ is a Buy, as the current market dynamics and technical indicators suggest further upside potential.